Arrowhead Pharma Files 8-K on Officer Compensatory Arrangements

Ticker: ARWR · Form: 8-K · Filed: Feb 22, 2024 · CIK: 879407

Sentiment: neutral

Topics: executive-changes, compensation, 8-K

TL;DR

**Arrowhead Pharma just filed an 8-K about executive compensation and officer changes, keep an eye on leadership moves!**

AI Summary

Arrowhead Pharmaceuticals, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 21, 2024. The filing pertains to Item 5.02, specifically regarding the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The company, based in Pasadena, CA, operates in the pharmaceutical preparations industry.

Why It Matters

This filing indicates potential changes in executive compensation or leadership, which can influence investor confidence and the company's strategic direction.

Risk Assessment

Risk Level: medium — Changes in executive compensation or officer appointments can signal strategic shifts or potential instability, warranting closer examination.

Key Players & Entities

FAQ

What was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 21, 2024.

What is the primary item discussed in this 8-K filing?

The primary item discussed is Item 5.02, which covers "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers."

Where is Arrowhead Pharmaceuticals, Inc. headquartered?

Arrowhead Pharmaceuticals, Inc. is headquartered at 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105.

What is the SEC File Number for Arrowhead Pharmaceuticals, Inc.?

The SEC File Number for Arrowhead Pharmaceuticals, Inc. is 001-38042.

What industry does Arrowhead Pharmaceuticals, Inc. operate in?

Arrowhead Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations industry (SIC 2834).

Filing Stats: 709 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2024-02-21 17:42:18

Key Financial Figures

Filing Documents

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: February 21, 2024 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Kenneth Myszkowski Kenneth Myszkowski Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing